Story
Novo Nordisk Inks €1.17 Billion Deal with Nanexa for Long-Acting Drug Tech
Summary
The Danish pharmaceutical giant will license Nanexa's PharmaShell platform to develop monthly or quarterly treatments for obesity and diabetes, in a deal featuring significant milestone payments and royalties.
Novo Nordisk has entered into an exclusive global licensing agreement with Swedish biotech firm Nanexa for its drug-delivery technology, a deal potentially valued at up to €1.165 billion. The partnership aims to develop long-acting formulations for treatments in obesity and type 2 diabetes, potentially shifting dosing from weekly to monthly or quarterly.
Deal Details
The agreement, announced after market hours on Thursday, gives Novo Nordisk exclusive rights to Nanexa’s PharmaShell platform for up to five development programs. Novo Nordisk will lead all global development and commercialization efforts for any products resulting from the collaboration.
The financial terms of the deal are structured with significant long-term incentives:
- Total potential value of up to €1.165 billion (approximately $1.26 billion).
- €615 million in combined upfront, development, and regulatory milestone payments.
- The remaining payments are tied to achieving specific sales milestones.
- Nanexa is also eligible to receive low-single-digit royalties on global net sales.
Strategic Importance
AdThis deal represents a strategic effort by Novo Nordisk to extend the product life cycle and competitive edge of its blockbuster cardiometabolic therapies. The core objective is to significantly reduce the frequency of administration, a key factor in patient adherence and preference.
By leveraging the PharmaShell technology, Novo Nordisk aims to create treatments that could be administered monthly or even quarterly, a substantial improvement over the current weekly injection schedule for many popular GLP-1 agonists. This would provide a significant advantage in an increasingly crowded market by enhancing patient convenience.
Market Context
The obesity and diabetes drug markets are among the most competitive and fastest-growing sectors in the pharmaceutical industry. Major players are actively pursuing innovations in drug delivery to differentiate their products and defend market share. Long-acting injectable formulations are a primary focus of this research, as they offer a clear benefit to patients managing chronic conditions.
Read next
More on Stocks
BMO Says AI Safety Concerns Unlikely to Slow Pace of Frontier Development
Despite genuine safety fears among industry leaders, top AI labs show little sign of slowing the release of more powerful models, according to a BMO note.
European Stocks Gain as Oil Price Dip Eases Sting of Surging Bond Yields
European markets advanced Friday, with a pullback in crude oil prices providing relief for key sectors. The gains came despite a continued surge in government bond yields, which have reached multi-year highs on expectations of prolonged central bank tightening.
Nikkei 225 Jumps 1.45% to One-Month High on Broad Sector Gains
Japanese stocks closed higher on Friday, with the Nikkei 225 index climbing 1.45% to reach its highest level in a month, driven by strong performance in the real estate and banking sectors.
HSBC Upgrades BP and TotalEnergies to Buy on Bullish Oil and Gas Forecasts
HSBC upgraded BP and TotalEnergies to Buy, raising its price forecasts for Brent crude and natural gas, which led to significantly higher earnings estimates across the energy sector.